

REMARKS

Following entry of this amendment, claims 1-3, 5, 7, 9, 11, 13, 15-33, 35, and 42-46 will be pending in the present application. Claims 4, 8, 10, 12 and 14 have been cancelled without prejudice to or disclaimer of the subject matter contained therein. Claims 1, 9, 11, 13, 15-17, 19, 20 and 27 have been amended. The amendments are supported by the originally-filed claims and specification. Applicants reserve the right to file continuing applications directed to the cancelled subject matter. No new matter is added by way of amendment.

The Office Action states that Applicants are required to elect a single group of claims selected from Groups I-XXIII. The Examiner has further required the selection of a single species to which the claims will be restricted if no generic claim is found allowable. Applicants hereby elect the claims of Group I (claims 1-33, 35, 43, and 44) for prosecution in the present case. Applicants further select the compound of Example 1 (4-[(Cyclopropylmethyl)(propyl)amino]-2-(trifluoromethyl)benzonitrile) for purposes of the initial search. Claims 1-3, 5, 7, 9, 11, 13, 15, 17-20, 27-33, 35, 43, and 44 read on the elected invention and the selected species.

The Office Action states that compounds of Formula I do not present a contribution of the prior art and cites page 279 of the 1989 Sigma catalog in support. The copy of the cited reference provided with the Office Action is very difficult to read, and the Applicants' representative has not been able to identify a compound that anticipates the genus of compounds currently encompassed by claim 1. The Applicants' representative has therefore interpreted the statement in the Office Action to indicate that the core of the compounds of Formula I are anticipated by the cited reference. If this interpretation of the statement in the Office Action is not correct, additional clarification is respectfully requested.

CONCLUSION

It is believed that the current application is now in condition for allowance. Early notice to this effect is solicited. If, in the opinion of the Examiner, an interview would expedite prosecution, the Examiner is invited to call the undersigned.

Respectfully submitted,

Kathryn L. Coulter

Kathryn L. Coulter
Attorney for Applicants
Reg. No. 45,889

Date: 2/23/2009
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988